Scholarlink

Background <p>Pneumococcal conjugate vaccines (PCVs) are designed to induce serotype-specific antibodies; however, antibodies raised against pneumococcal polysaccharides in the vaccine can also cross-react to other serotypes based on structural similarities. Cross-reactivity has been demonstrated for some licensed PCVs and is a worthy consideration to broaden protection against pneumococcal disease. This secondary analysis examined cross-reactive immune responses within serogroups 6 and 15 following vaccination with V116, an adult-specific PCV.</p> Methods <p>Antibody levels were assessed across five phase 3 clinical studies at baseline and 30 days following vaccination.</p> Results <p>V116 elicits functional antibodies to vaccine serotypes 6A and 15C that result in cross-reactive antibodies to serotypes 6C and 15B, respectively, as assessed by opsonophagocytic activity responses from pre- to post-vaccination and IgG geometric mean concentrations.</p> Conclusions <p>V116-induced antibodies demonstrate cross-reactivity to serotypes 6C and 15B, suggesting protective immune responses may be raised against these non-vaccine serotypes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cross reactivity within pneumococcal serogroups 6 and 15 following adult vaccination with pneumococcal conjugate vaccine V116

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月29日

查看全文
  • Jianing Li,
  • Heather L. Platt,
  • Wenyu Hu,
  • Weifeng Xu,
  • Timothy J. Chapman,
  • Katrina M. Nolan,
  • Jonathan Hartzel,
  • Ulrike K. Buchwald

摘要

Background

Pneumococcal conjugate vaccines (PCVs) are designed to induce serotype-specific antibodies; however, antibodies raised against pneumococcal polysaccharides in the vaccine can also cross-react to other serotypes based on structural similarities. Cross-reactivity has been demonstrated for some licensed PCVs and is a worthy consideration to broaden protection against pneumococcal disease. This secondary analysis examined cross-reactive immune responses within serogroups 6 and 15 following vaccination with V116, an adult-specific PCV.

Methods

Antibody levels were assessed across five phase 3 clinical studies at baseline and 30 days following vaccination.

Results

V116 elicits functional antibodies to vaccine serotypes 6A and 15C that result in cross-reactive antibodies to serotypes 6C and 15B, respectively, as assessed by opsonophagocytic activity responses from pre- to post-vaccination and IgG geometric mean concentrations.

Conclusions

V116-induced antibodies demonstrate cross-reactivity to serotypes 6C and 15B, suggesting protective immune responses may be raised against these non-vaccine serotypes.